Curis Inc (CRIS): EBITDA
-$5.54M
Year ended 2025-12-31
-$8.68M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$5.54M | n/m | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | -$44.34M | n/m | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | -$48.08M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$52.79M | n/m | 2024-02-08, From 2022-01-01 |
| 2021-12-31 | -$41.91M | n/m | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | -$24.75M | n/m | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | -$24.23M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$29.16M | n/m | 2020-03-19, From 2018-01-01 |
| 2017-12-31 | -$49.52M | n/m | 2019-03-26, From 2017-01-01 |
| 2016-12-31 | -$57.85M | n/m | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | -$56.32M | n/m | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | -$15.71M | n/m | 2017-03-09, From 2014-01-01 |
| 2013-12-31 | -$9.27M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$18.49M | n/m | 2015-02-24, From 2012-01-01 |
| 2011-12-31 | -$7.10M | n/m | 2014-03-13, From 2011-01-01 |
| 2010-12-31 | -$4.95M | n/m | 2013-03-13, From 2010-01-01 |
| 2009-12-31 | -$9.29M | n/a | 2012-02-29, From 2009-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Curis Inc (CRIS) | 2025-12-31 | -$5.54M | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | -$22.60M | n/m |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | -$132.91M | n/m |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | -$144.70M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$134.80M | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$35.92M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$144.07M | n/m |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$5.31M | n/m |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | -$90.85M | n/m |
Compare CRIS, ACOG, TCRX, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗